Zenagamtide vs CagriSema: Single Molecule vs Fixed-Dose Combination

Are Zenagamtide and CagriSema the Same Drug?

No. Despite both targeting GLP-1 and amylin receptors, zenagamtide and CagriSema are structurally different drugs with different designs. Zenagamtide (also known as amycretin) is a single unimolecular peptide that activates both GLP-1 and amylin receptors from a single molecular backbone. CagriSema is a fixed-dose combination of two separate drugs — cagrilintide (a long-acting amylin analog) and semaglutide (a GLP-1 receptor agonist) — co-formulated in one injection.

The distinction matters because it affects manufacturing complexity, dosing flexibility, pharmacokinetics, and long-term development potential. Both drugs come from Novo Nordisk, but they represent two fundamentally different approaches to dual GLP-1/amylin receptor activation.

What Is Zenagamtide (Amycretin)?

Zenagamtide is Novo Nordisk’s unimolecular dual GLP-1/amylin receptor agonist. It is a single peptide engineered to activate both GLP-1 and amylin receptors simultaneously. In Phase 1b/2 data, subcutaneous zenagamtide demonstrated approximately 22% weight loss at around 36 weeks. Our full zenagamtide compound profile covers mechanism, trial status, and data in detail.

Notably, Novo Nordisk is also developing an oral formulation of zenagamtide, currently in Phase 2 trials (NCT06490861, NCT06490874). If successful, this would make zenagamtide one of the first oral dual GLP-1/amylin agonists — a significant practical advantage over injection-only competitors including CagriSema.

What Is CagriSema?

CagriSema is Novo Nordisk’s fixed-dose combination of cagrilintide (a long-acting amylin analog) and semaglutide (a GLP-1 receptor agonist), delivered as a single subcutaneous injection. The Phase 3 REDEFINE program showed 22.7% weight loss in REDEFINE 1 and 15.7% in REDEFINE 2 (patients with type 2 diabetes).

Novo Nordisk filed a New Drug Application (NDA) for CagriSema with the FDA on December 18, 2025, making it the company’s most advanced dual-receptor obesity drug. An FDA decision is expected in late 2026. As a fixed-dose combination, the ratio of cagrilintide to semaglutide is predetermined and cannot be adjusted independently for individual patients. For the full REDEFINE data set, see our CagriSema amylin and GLP-1 profile.

How Do Their Approaches Differ?

The core difference is architectural. CagriSema takes two proven molecules — each already validated independently — and combines them in a single syringe at a fixed ratio. This approach leverages existing clinical evidence for both components but introduces the constraints of fixed-ratio dosing and two-molecule manufacturing.

Zenagamtide takes the opposite approach: engineer a single peptide that does the work of two. This unimolecular design eliminates the need to balance two separate drugs in a fixed ratio. Instead, the receptor activation profile is built into the molecule itself. The trade-off is that zenagamtide requires novel molecular engineering and does not yet have the Phase 3 dataset that CagriSema has generated. Our retatrutide vs tirzepatide vs CagriSema analysis benchmarks how these dual-pathway drugs stack up against triple agonists.

Why Does the Single-Molecule Design Matter?

The unimolecular approach offers several theoretical and practical advantages. Manufacturing is simpler because only one molecule needs to be synthesized, purified, and formulated — versus two for CagriSema. Pharmacokinetic optimization is more straightforward because the two activities are coupled in a single molecule rather than relying on two separate drugs with potentially different absorption and clearance profiles.

Perhaps most importantly, the single-molecule design enables oral formulation. Developing an oral version of a fixed-dose combination like CagriSema would require solving the oral delivery problem for two separate peptides simultaneously — a significantly more complex challenge. Zenagamtide’s oral Phase 2 program demonstrates that the unimolecular approach simplifies this path. For another amylin monotherapy comparison, see our petrelintide vs CagriSema breakdown.

What Does This Mean for Novo Nordisk’s Pipeline?

Novo Nordisk is running a deliberate two-generation strategy. CagriSema is the near-term product — NDA filed, Phase 3 data complete, FDA decision expected late 2026. It is designed to compete immediately against tirzepatide (Zepbound/Mounjaro) and the Wegovy franchise.

Zenagamtide is the next-generation platform. It is still in Phase 2 and years from potential approval, but its unimolecular design and oral development program position it as a potential successor to CagriSema. If zenagamtide delivers comparable or superior efficacy with the added convenience of an oral option, it could eventually become the preferred Novo Nordisk dual-receptor product.

This is not unusual in pharmaceutical development. Companies routinely develop multiple products targeting the same biology at different stages of maturity, ensuring both near-term revenue and long-term competitive positioning. For a wider view of the competitive landscape, explore our best research peptides 2026 guide.